Form 8-K

8-K — Telomir Pharmaceuticals, Inc.

Accession: 0001493152-26-042483

Filed: 2026-09-14

Period: 2026-09-14

CIK: 0001971532

SIC: 2834 (PHARMACEUTICAL PREPARATIONS)

Item: Regulation FD Disclosure

Item: Financial Statements and Exhibits

Documents

8-K — form8-k.htm (Primary)

EX-99.1 (ex99-1.htm)

XML — IDEA: XBRL DOCUMENT (R1.htm)

8-K

8-K (Primary)

Filename: form8-k.htm · Sequence: 1

false

0001971532

2026-09-14

iso4217:USD

xbrli:shares

iso4217:USD

xbrli:shares

UNITED

STATES

SECURITIES

AND EXCHANGE COMMISSION

WASHINGTON,

D.C. 20549

FORM

8-K

CURRENT

REPORT

Pursuant

to Section 13 or 15(d) of the

Securities

Exchange Act of 1934

Date

of Report (Date of earliest event reported): September 14, 2026

TELOMIR

PHARMACEUTICALS, INC.

(Exact

Name of Registrant as Specified in its Charter)

Florida

001-41952

87-2606031

(State

or Other Jurisdiction

(Commission

(IRS

Employer

Incorporation)

File

Number)

Identification

No.)

100

SE 2nd St, Suite 2000, #1009

Miami,

Florida 33131

(Address

of Principal Executive Offices)

Registrant’s

telephone number, including area code: (786) 396-6723

Not

Applicable

(Former

Name or Former Address, if Changed Since Last Report)

Check

the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under

any of the following provisions:

☐

Written

communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐

Soliciting

material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐

Pre-commencement

communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐

Pre-commencement

communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities

registered pursuant to Section 12(b) of the Act:

Title

of each class

Trading

Symbol

Name

of each exchange on which registered

Common

Stock, no par value

TELO

The

Nasdaq Stock Market LLC

Indicate

by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405

of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging

growth company ☒

an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying

with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item

7.01 Regulation FD Disclosure.

September 14, 2026, Telomir Pharmaceuticals, Inc. (the “Company”) issued a press release announcing new research findings

from The Ohio State University College of Veterinary Medicine demonstrating that Telomir-Zn produces inhibition of cell growth across

human and canine osteosarcoma models.

The

study examined Telomir-Zn across three osteosarcoma cell line models: HOS (human), D17 (canine), and Abrams (canine). Researchers evaluated

the dose-dependent anti-tumor activity of Telomir-Zn across all three models, with all three osteosarcoma cell lines demonstrating growth

inhibition at similar low drug concentrations. The findings support further translational investigation.

The

Company’s immediate clinical focus remains its Telomir-Zn program in advanced or metastatic triple-negative breast cancer (“TNBC”),

which is advancing toward site initiation and Phase 1/2 patient enrollment under an active Investigational New Drug application cleared

by the U.S. Food and Drug Administration. In parallel, based on the osteosarcoma findings, the Company is in discussions with The Ohio

State University College of Veterinary Medicine and is assessing next steps for a potential in vivo efficacy study in canine osteosarcoma.

Such a study could support potential veterinary indication development while also providing translational insight relevant to human osteosarcoma.

The Company believes this parallel development pathway may provide an additional opportunity to explore the potential applicability of

Telomir-Zn across multiple oncology indications while the TNBC program advances clinically.

copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

The

information contained in this Item 7.01, including Exhibit 99.1, is being furnished and shall not be deemed “filed” for purposes

of Section 18 of the Securities Exchange Act of 1934, as amended, nor shall it be incorporated by reference into any filing of the Company,

except as expressly set forth by specific reference in such filing.

Cautionary Note Regarding Forward-Looking Statements

This

report contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995.

These forward-looking statements generally may be identified by the use of words such as “anticipate,” “expect,”

“plan,” “can,” “could,” “would,” “may,” “will,” “believe,”

“estimate,” “forecast,” “goal,” “project,” “guidance,” “potential,”

“intend,” “seek,” “target” and other words of similar meaning, although not all forward-looking statements

include these words. Forward-looking statements may include, but are not limited to, statements regarding the therapeutic potential,

mechanism of action, development plans, regulatory pathway, safety profile, efficacy, anticipated clinical development, commercialization

prospects, market opportunity and future development of Telomir-Zn, including its potential applications in oncology and other disease

indications, and the Company’s other research and development programs.

These

forward-looking statements are based on current expectations, estimates, forecasts and projections, as well as management’s current

beliefs and assumptions, and are subject to significant risks and uncertainties that could cause actual results to differ materially

from those expressed or implied by such statements. These risks and uncertainties include, among others, risks related to preclinical

and clinical development; the initiation, timing, progress and results of clinical trials and other studies; the ability to recruit and

enroll patients in clinical trials; the safety and efficacy of Telomir-Zn; the Company’s ability to obtain and maintain regulatory

approvals; the timing and outcome of regulatory submissions and interactions with regulatory authorities; reliance on third-party manufacturers,

contract research organizations and other service providers; intellectual property protection; the Company’s ability to obtain

additional financing; commercialization and market acceptance of the Company’s product candidates, if approved; competition; market

conditions; and the other risks identified under the heading “Risk Factors” contained in the Company’s Annual Report

on Form 10-K and the Company’s subsequent filings with the U.S. Securities and Exchange Commission (“SEC”).

Forward-looking

statements contained in this report speak only as of the date of this report, and the Company undertakes no obligation to update or revise

these forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable

law.

Investors

are cautioned not to place undue reliance on these forward-looking statements. Additional information regarding these and other risks

and uncertainties is contained in the Company’s filings with the SEC, including its Annual Report on Form 10-K and subsequent filings,

available at www.sec.gov and in the Investors section of the Company’s website at www.telomirpharma.com. Forward-looking

statements should be considered in light of these risks and uncertainties.

Item

9.01 Financial Statements and Other Exhibits.

(d)

Exhibits.

Exhibit

No.

Description

99.1

Press Release of Telomir Pharmaceuticals, Inc., dated September 14, 2026

104

Cover

Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant

to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by

the undersigned hereunto duly authorized.

TELOMIR

PHARMACEUTICALS, INC.

Dated:

September 14, 2026

By:

/s/

Erez Aminov

Name:

Erez

Aminov

Title:

Chief

Executive Officer

EX-99.1

Filename: ex99-1.htm · Sequence: 2

Exhibit

99.1

Telomir

Announces Research with The Ohio State University Demonstrating In-Vitro Anti-Cancer Activity in Human and Canine Osteosarcoma

Models

Preclinical

Findings Support Parallel Development Pathway in Canine Osteosarcoma as TNBC Program Advances Toward Site Initiation

MIAMI,

Sept. 14 (GLOBE NEWSWIRE) — Telomir Pharmaceuticals, Inc. (NASDAQ:TELO), a clinical-stage biotechnology company developing

small-molecule therapeutics targeting epigenetic and metabolic drivers of cancer, announced new research findings from The Ohio State

University College of Veterinary Medicine demonstrating that Telomir-Zn produces inhibition of cell growth across human and canine osteosarcoma

models. The findings establish a translational foundation for evaluating the compound in a naturally occurring disease setting while

the company’s TNBC program simultaneously advances toward site initiation and Phase 1/2 patient enrollment.

Research

Findings

Conducted

under the direction of Shay Bracha, DVM, MS, DACVIM (Oncology) at Ohio State’s College of Veterinary Medicine, the study examined

Telomir-Zn across three osteosarcoma cell line models: HOS (human), D17 (canine), and Abrams (canine). Researchers evaluated the dose-dependent

anti-tumor activity of the compound across all three models.

All

three osteosarcoma cell lines demonstrated growth inhibition at similar low drug concentrations. “Osteosarcoma in large-breed dogs

remains devastating, with limited treatment options and poor outcomes,” noted Bracha, an associate professor at The Ohio State

University College of Veterinary Medicine. “These findings suggest Telomir-Zn may offer a meaningful therapeutic opportunity

for veterinary patients. The consistency of anti-tumor activity across both canine and human cell lines is particularly compelling because

it positions us to explore efficacy in naturally occurring canine osteosarcoma—a model that could accelerate development for both

animals and humans.”

These

results validate the therapeutic potential of Telomir-Zn in osteosarcoma and support further translational investigation.

Osteosarcoma:

An Unmet Clinical Need

Osteosarcoma

is the most common primary bone malignancy in children and young adults. Despite decades of chemotherapy-based treatment, survival rates

for metastatic disease remain below 30%, with minimal improvement over three decades. In veterinary medicine, osteosarcoma is similarly

devastating in large-breed dogs, accounting for the majority of primary bone tumors.

The

biological similarities between canine and human osteosarcoma, including genetics, tumor biology, and therapeutic response patterns,

make the canine model one of the most clinically predictive disease models available for translational research.

Strategic

Development Pathway

Based

on these findings, Telomir is assessing osteosarcoma development in canine models as a potential therapeutic pathway, which could support

both veterinary indication development and translational advancement toward human osteosarcoma:

● Track

1: TNBC in Humans — The company’s TNBC program is advancing toward site initiation

and Phase 1/2 patient enrollment under an active IND cleared by the FDA, targeting advanced

or metastatic triple-negative breast cancer.

● Track

2: Osteosarcoma in Dogs — Based on these preclinical findings, Telomir is in conversations

with The Ohio State University College of Veterinary Medicine and assessing next steps for

a potential in vivo efficacy study in canine osteosarcoma. Such research could accelerate

clinical development in canine and human osteosarcoma.

While

the company’s immediate focus remains advancing TNBC toward site initiation and Phase 1/2 patient enrollment, these preclinical

findings position potential osteosarcoma development in canine models as a strategic opportunity. If pursued, such a dual-pathway approach

could expand the therapeutic indication profile while advancing our platform.

The

Iron-Modulation Platform

Telomir-Zn

targets intracellular iron and copper homeostasis to modulate epigenetic pathways. The mechanism involves disruption of intracellular

labile iron pools and inhibition of iron-dependent histone demethylases (KDMs), which reverses cancer-associated epigenetic silencing.

The

company’s strategic focus is triple-negative breast cancer, where the TNBC program is advancing toward site initiation and Phase

1/2 patient enrollment. The osteosarcoma preclinical findings provide an additional translational opportunity to validate the mechanism

in a naturally occurring disease model (canine) while simultaneously advancing the lead TNBC indication.

Forward

Outlook

Erez

Aminov, Chairman and CEO of Telomir Pharmaceuticals, said: “This research opens a strategic opportunity to develop Telomir-Zn

across multiple oncology indications. Our TNBC program is advancing toward site initiation and Phase 1/2 patient enrollment, and we are

assessing next steps for potential osteosarcoma development. If successful with either indication, this multi-pronged approach could

establish Telomir-Zn as a platform therapy targeting aggressive malignancies, meaningfully expanding our therapeutic scope.”

About

Telomir Pharmaceuticals

Telomir

Pharmaceuticals, Inc. (NASDAQ:TELO) is a clinical-stage biotechnology company developing small-molecule therapeutics targeting epigenetic

and metabolic pathways implicated in cancer. The Company’s lead program, Telomir-Zn, is designed to modulate intracellular metal

homeostasis and epigenetic regulation and has received Investigational New Drug (IND) clearance from the U.S. Food and Drug Administration

for a Phase 1/2 clinical trial in patients with advanced or metastatic triple-negative breast cancer. For more information, please visit

https://telomirpharma.com/.

Telomir Pharmaceuticals Forward-Looking Statements

This

press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of

1995. These forward-looking statements generally can be identified by the use of words such as “anticipate,” “expect,”

“plan,” “can,” “could,” “would,” “may,” “will,” “believe,”

“estimate,” “forecast,” “goal,” “project,” “guidance,” “potential,”

“intend,” “seek,” “target” and other words of similar meaning, although not all forward-looking statements

include these words.

Forward-looking

statements may include, but are not limited to, statements regarding the therapeutic potential, mechanism of action, development plans,

regulatory pathway, safety profile, clinical utility, market opportunity, and future development of Telomir-1 (Telomir-Zn) and the Company’s

other product candidates. Forward-looking statements may also include statements regarding the significance of the published preclinical

findings, the relevance of such findings to the Company’s oncology development programs, the advancement of the Company’s

Phase 1/2 TNBC clinical trial, and the potential applicability of Telomir-Zn across multiple disease areas.

These

forward-looking statements are based on current expectations, estimates, forecasts, and projections, as well as management’s beliefs

and assumptions, and are subject to significant risks and uncertainties that could cause actual results to differ materially from those

expressed or implied by such statements. These risks and uncertainties include, among others, risks related to preclinical and clinical

development, the ability to obtain regulatory approvals, the outcome of future studies, reliance on third parties, intellectual property

protection, financing needs, market conditions, and the other risks identified under the heading “Risk Factors” contained

in the Company’s Annual Report on Form 10-K and the Company’s other filings with the U.S. Securities and Exchange Commission

(“SEC”).

Forward-looking

statements contained in this press release speak only as of the date hereof, and the Company undertakes no obligation to update or revise

such statements, whether as a result of new information, future events, or otherwise, except as required by applicable law.

caution investors not to place undue reliance on the forward-looking statements contained in this press release. You are encouraged to

read our filings with the SEC, available at the SEC website and in the “Investors” section of our website, for a discussion

of these and other risks and uncertainties.

Telomir

Pharmaceuticals Contact Information

Krystina Quintana

Email:

info@telomirpharma.com

Phone: (786) 396-6723

XML — IDEA: XBRL DOCUMENT

XML

Filename: R1.htm · Sequence: 7

v3.26.3

Cover

Sep. 14, 2026

Cover [Abstract]

Document Type

8-K

Amendment Flag

false

Document Period End Date

Sep. 14, 2026

Entity File Number

001-41952

Entity Registrant Name

TELOMIR

PHARMACEUTICALS, INC.

Entity Central Index Key

0001971532

Entity Tax Identification Number

87-2606031

Entity Incorporation, State or Country Code

Entity Address, Address Line One

100

SE 2nd St

Entity Address, Address Line Two

Suite 2000

Entity Address, Address Line Three

#1009

Entity Address, City or Town

Miami

Entity Address, State or Province

Entity Address, Postal Zip Code

33131

City Area Code

(786)

Local Phone Number

396-6723

Written Communications

false

Soliciting Material

false

Pre-commencement Tender Offer

false

Pre-commencement Issuer Tender Offer

false

Title of 12(b) Security

Common

Stock, no par value

Trading Symbol

TELO

Security Exchange Name

NASDAQ

Entity Emerging Growth Company

true

Elected Not To Use the Extended Transition Period

false

- Definition

Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.

+ References

No definition available.

+ Details

Name:

dei_AmendmentFlag

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Area code of city

+ References

No definition available.

+ Details

Name:

dei_CityAreaCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Cover page.

+ References

No definition available.

+ Details

Name:

dei_CoverAbstract

Namespace Prefix:

dei_

Data Type:

xbrli:stringItemType

Balance Type:

Period Type:

duration

- Definition

For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.

+ References

No definition available.

+ Details

Name:

dei_DocumentPeriodEndDate

Namespace Prefix:

dei_

Data Type:

xbrli:dateItemType

Balance Type:

Period Type:

duration

- Definition

The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.

+ References

No definition available.

+ Details

Name:

dei_DocumentType

Namespace Prefix:

dei_

Data Type:

dei:submissionTypeItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 1 such as Attn, Building Name, Street Name

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine1

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 2 such as Street or Suite number

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine2

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 3 such as an Office Park

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine3

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the City or Town

+ References

No definition available.

+ Details

Name:

dei_EntityAddressCityOrTown

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Code for the postal or zip code

+ References

No definition available.

+ Details

Name:

dei_EntityAddressPostalZipCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the state or province.

+ References

No definition available.

+ Details

Name:

dei_EntityAddressStateOrProvince

Namespace Prefix:

dei_

Data Type:

dei:stateOrProvinceItemType

Balance Type:

Period Type:

duration

- Definition

A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityCentralIndexKey

Namespace Prefix:

dei_

Data Type:

dei:centralIndexKeyItemType

Balance Type:

Period Type:

duration

- Definition

Indicate if registrant meets the emerging growth company criteria.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityEmergingGrowthCompany

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Securities Act

-Number 7A

-Section B

-Subsection 2

+ Details

Name:

dei_EntityExTransitionPeriod

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.

+ References

No definition available.

+ Details

Name:

dei_EntityFileNumber

Namespace Prefix:

dei_

Data Type:

dei:fileNumberItemType

Balance Type:

Period Type:

duration

- Definition

Two-character EDGAR code representing the state or country of incorporation.

+ References

No definition available.

+ Details

Name:

dei_EntityIncorporationStateCountryCode

Namespace Prefix:

dei_

Data Type:

dei:edgarStateCountryItemType

Balance Type:

Period Type:

duration

- Definition

The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityRegistrantName

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityTaxIdentificationNumber

Namespace Prefix:

dei_

Data Type:

dei:employerIdItemType

Balance Type:

Period Type:

duration

- Definition

Local phone number for entity.

+ References

No definition available.

+ Details

Name:

dei_LocalPhoneNumber

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 13e

-Subsection 4c

+ Details

Name:

dei_PreCommencementIssuerTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14d

-Subsection 2b

+ Details

Name:

dei_PreCommencementTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Title of a 12(b) registered security.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b

+ Details

Name:

dei_Security12bTitle

Namespace Prefix:

dei_

Data Type:

dei:securityTitleItemType

Balance Type:

Period Type:

duration

- Definition

Name of the Exchange on which a security is registered.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection d1-1

+ Details

Name:

dei_SecurityExchangeName

Namespace Prefix:

dei_

Data Type:

dei:edgarExchangeCodeItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14a

-Subsection 12

+ Details

Name:

dei_SolicitingMaterial

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Trading symbol of an instrument as listed on an exchange.

+ References

No definition available.

+ Details

Name:

dei_TradingSymbol

Namespace Prefix:

dei_

Data Type:

dei:tradingSymbolItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Securities Act

-Number 230

-Section 425

+ Details

Name:

dei_WrittenCommunications

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration